Sign Out
Keppra is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.
Keppra is indicated as adjunctive therapy in the treatment of: partial onset seizures with or without secondary generalisation in adults, adolescents, children from 1 month of age with epilepsy; myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy; primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.
Keppra 100 mg/ml concentrate for solution for infusion is alternative for patients (adults and children from 4 years of age) when oral administration is temporarily not feasible.
